Related Experiment Video
Updated: Mar 2, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
25.1K
Botulinum Toxin Therapy for Parkinson's Disease
Aparna Wagle Shukla1, Irene A Malaty1
1Department of Neurology, University of Florida, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida.
Seminars in Neurology
|May 17, 2017
Summary
Botulinum toxin (BoNT) is a valuable tool for managing Parkinson's disease (PD) symptoms like dystonia and sialorrhea. While its use is expanding to other PD-related issues, more research is needed on its effectiveness and side effects in PD patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Botulinum toxin (BoNT) is a common therapy for Parkinson's disease (PD) symptoms.
- It effectively treats cervical dystonia, blepharospasm, sialorrhea, and hyperactive bladder.
Purpose of the Study:
- To review the current literature on BoNT applications for PD-related motor and nonmotor disorders.
- To discuss the evolving evidence for BoNT efficacy and side effect profiles in PD patients.
Main Methods:
- Literature review of studies on BoNT use in Parkinson's disease.
- Analysis of evidence for efficacy and side effects in various PD symptoms.
Main Results:
- BoNT is effective for dystonia and sialorrhea in PD.
- Evidence for other PD symptoms (tremors, constipation, dysphagia, etc.) is still developing, often based on non-PD populations.
- BoNT treatment has localized side effects and does not impede dopaminergic therapy.
Conclusions:
- Botulinum toxin is an important therapeutic option for Parkinson's disease.
- Further research is needed to fully understand BoNT's role in managing diverse PD symptoms and its specific side effect profile in this population.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
01:20Myasthenia Gravis: Overview and Treatment
3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K